Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Rivaroxaban
Related studies linked through entity extraction aliases.
Rivaroxaban in Pediatric Patients With DVT
- Status
- COMPLETED
- Phase
- PHASE4
Emulation of the RECORD3 Trial Using Healthcare Claims Data
- Status
- COMPLETED
- Phase
- N/A
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
- Status
- RECRUITING
- Phase
- PHASE4
Thromboprophylaxis in Lower Limb Immobilisation
- Status
- RECRUITING
- Phase
- PHASE3
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
- Status
- RECRUITING
- Phase
- PHASE4
Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients
- Status
- RECRUITING
- Phase
- PHASE3
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
- Status
- RECRUITING
- Phase
- PHASE4
Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data
- Status
- COMPLETED
- Phase
- N/A
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- Status
- COMPLETED
- Phase
- N/A
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
- Status
- COMPLETED
- Phase
- PHASE3
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
- Status
- COMPLETED
- Phase
- N/A
Anticoagulation in Patients With Venous Thromboembolism and Cancer
- Status
- COMPLETED
- Phase
- N/A
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
- Status
- COMPLETED
- Phase
- PHASE4